Abstract
HIV-1 integrase (IN), which has no cellular counterpart, has been intensely studied over the past 15 years and has been fully validated as a therapeutic target with the first FDA approved IN inhibitor raltegravir. The quinolone acid GS-9137 (elvitegravir), which most probably will become the next candidate of IN inhibitors, is in the process of enrolling patients in the phase III clinical trials. This review focuses on small-molecular of quinolone acid derivatives, which have the similar pharmacophore of β-diketoacids, as integrase inhibitors with antiviral activity.
Keywords: Drug discovery, diketoacides, HIV-1, inhibitors, integrase, quinolone acid derivatives, Integrase Inhibitors, Quinolone Acid, AIDS, HIV-1 integrase (IN), GS-9137, HIV-1, inhibitors, HIV-1 replication process, Transcriptase inhibitors (NRTIs), Co-receptor inhibitor (CRI), Virus-drug resistance, Antiretroviral therapy (HAART), Catalytic core domain (CCD), Inhibit viral integration of diketo-acid derivatives, NADPH-dependent, 3D-QSAR, Structure-activity relationship (SAR), Anti-IN activity, Inhibitory potency, Current antiviral drugs, Fusion inhibitor, Half maximal inhibitory concentration, Reverse transcriptase
Mini-Reviews in Medicinal Chemistry
Title: Development of Integrase Inhibitors of Quinolone Acid Derivatives for Treatment of AIDS: An Overview
Volume: 10 Issue: 11
Author(s): Z. G. Luo, J. J. Tan, Y. Zeng, C. X. Wang and L. M. Hu
Affiliation:
Keywords: Drug discovery, diketoacides, HIV-1, inhibitors, integrase, quinolone acid derivatives, Integrase Inhibitors, Quinolone Acid, AIDS, HIV-1 integrase (IN), GS-9137, HIV-1, inhibitors, HIV-1 replication process, Transcriptase inhibitors (NRTIs), Co-receptor inhibitor (CRI), Virus-drug resistance, Antiretroviral therapy (HAART), Catalytic core domain (CCD), Inhibit viral integration of diketo-acid derivatives, NADPH-dependent, 3D-QSAR, Structure-activity relationship (SAR), Anti-IN activity, Inhibitory potency, Current antiviral drugs, Fusion inhibitor, Half maximal inhibitory concentration, Reverse transcriptase
Abstract: HIV-1 integrase (IN), which has no cellular counterpart, has been intensely studied over the past 15 years and has been fully validated as a therapeutic target with the first FDA approved IN inhibitor raltegravir. The quinolone acid GS-9137 (elvitegravir), which most probably will become the next candidate of IN inhibitors, is in the process of enrolling patients in the phase III clinical trials. This review focuses on small-molecular of quinolone acid derivatives, which have the similar pharmacophore of β-diketoacids, as integrase inhibitors with antiviral activity.
Export Options
About this article
Cite this article as:
G. Luo Z., J. Tan J., Zeng Y., X. Wang C. and M. Hu L., Development of Integrase Inhibitors of Quinolone Acid Derivatives for Treatment of AIDS: An Overview, Mini-Reviews in Medicinal Chemistry 2010; 10 (11) . https://dx.doi.org/10.2174/1389557511009011046
DOI https://dx.doi.org/10.2174/1389557511009011046 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Perspectives of Wasp Venom
Protein & Peptide Letters Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Phytochemistry and Pharmacology of Indian Traditional Plant Hyssop (<i>Hyssopus officinalis</i> L.): A Review
The Natural Products Journal Mechanism of Action of Chloroquine/Hydroxychloroquine for Covid-19 Infection
Coronaviruses Design of Ester Prodrugs to Enhance Oral Absorption of Poorly Permeable Compounds: Challenges to the Discovery Scientist
Current Drug Metabolism Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Thiophene and Its Analogs as Prospective Antioxidant Agents: A Retrospective Study
Mini-Reviews in Medicinal Chemistry Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design COVID-19 Treatment Success After Repeat Courses of Azithromycin: A Report of Three Cases
Infectious Disorders - Drug Targets Study on Molecular Anti-tumor Mechanism of 2-Thiohydantoin Derivative based on Molecular Docking and Bioinformatic Analyses
Current Topics in Medicinal Chemistry Studies on Chemistry, Spectroscopy and Antioxidant Activities of Chromium(III)-Hydrazide Complexes
Medicinal Chemistry Disaggregation of Tau as a Therapeutic Approach to Tauopathies
Current Alzheimer Research The Rationale and Development of New Drugs to Treat HIV Infection
Medicinal Chemistry Identification of Kaempferol as Viral Entry Inhibitor and DL-Arginine as Viral Replication Inhibitor from Selected Plants of Indian Traditional Medicine against COVID-19: An <i>in silico</i> Guided in vitro Approach
Current Computer-Aided Drug Design Small Molecule Approaches Toward the Non-Microbicidal Modulation of Bacterial Biofilm Growth and Maintenance
Anti-Infective Agents in Medicinal Chemistry Antimicrobial Activities of 1-H-Benzimidazole-based Molecules
Current Topics in Medicinal Chemistry An Effective COVID-19 CT Image Denoising Method Based on a Deep Convolutional Neural Network
Recent Advances in Computer Science and Communications The Newfangled Upsurge of Double Mutant SARS-CoV-2 Virus in 2021-Current Scenario and Inspecting Ahead
Recent Advances in Anti-Infective Drug Discovery Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research New Derivatives of BM212: A Class of Antimycobacterial Compounds Based on the Pyrrole Ring as a Scaffold
Mini-Reviews in Medicinal Chemistry